Scientists Uncover WNT5a Pathway as Key Driver of Heart Disease in Rare Muscular Dystrophy
A new mechanism linking LMNA mutations to cardiac arrhythmias and dysfunction in Emery-Dreifuss muscular dystrophy points to promising drug targets.
Summary
Researchers studying a rare genetic disorder called Emery-Dreifuss muscular dystrophy (EDMD) have discovered why mutations in the LMNA gene cause serious heart problems. Using patient-derived stem cells converted into heart muscle cells, they found that a mutated LMNA protein reduces activity of a signaling molecule called WNT5a. This disrupts the normal assembly of actin filaments — structural proteins critical for heart cell function. The result is disorganized heart muscle, abnormal nuclear shape, impaired electrical signaling, and weak contractions. Importantly, restoring WNT5a signaling or stabilizing actin filaments with drugs reversed these harmful effects in lab models. A mouse model carrying the same mutation also showed heart rhythm problems under stress. These findings open new therapeutic avenues for a condition where roughly 20% of patients eventually need a heart transplant.
Detailed Summary
Emery-Dreifuss muscular dystrophy (EDMD) is a rare but devastating genetic disease causing joint contractures, muscle wasting, and life-threatening heart problems including arrhythmias and heart block. Mutations in the LMNA gene — which encodes a structural nuclear protein called lamin A/C — are responsible for many severe cardiac cases, yet the molecular chain of events connecting these mutations to heart disease has remained poorly understood.
This study recruited five EDMD patients carrying LMNA mutations and generated patient-specific induced pluripotent stem cells (iPSCs), which were then differentiated into cardiomyocytes (heart muscle cells). Gene-corrected isogenic controls and a knock-in mouse model carrying the Lmna L204P mutation were also created to isolate the effects of the mutation.
The patient-derived heart cells showed disorganized sarcomeres, abnormal nuclear envelopes, arrhythmias, and weakened contractions. Multi-omics analysis revealed that mutant LMNA directly reduces chromatin accessibility at the WNT5A gene promoter, suppressing WNT5a protein production. This in turn inactivates RhoA signaling, causing actin filaments to depolymerize. Disrupted actin dynamics deform the nuclear envelope, impair contractile function, and critically block the trafficking of connexin 43 (Cx43) — a gap junction protein essential for coordinated electrical signaling between heart cells. Reduced Cx43 at cell borders explains the arrhythmic phenotype.
Pharmacological rescue experiments were striking: supplementing exogenous WNT5a, activating RhoA, or stabilizing actin polymerization all reversed the pathological phenotypes in patient-derived cells and engineered heart tissues. The knock-in mice developed cardiac arrhythmias under sympathetic stress, validating the model in vivo.
These findings establish a coherent mechanistic pathway from LMNA mutation to cardiac disease and identify WNT5a/RhoA signaling and actin stabilization as actionable therapeutic targets for EDMD-related cardiomyopathy.
Key Findings
- LMNA mutations suppress WNT5a transcription by reducing chromatin accessibility at its promoter in heart cells.
- WNT5a/RhoA inactivation causes actin depolymerization, deforming nuclear envelopes and impairing heart cell contraction.
- Disrupted actin dynamics block connexin 43 trafficking to cell borders, directly causing arrhythmias.
- Restoring WNT5a, activating RhoA, or stabilizing actin filaments pharmacologically rescued cardiac phenotypes in lab models.
- Knock-in mice with the Lmna L204P mutation developed arrhythmias under sympathetic stress, confirming in vivo relevance.
Methodology
The study used patient-derived iPSC-cardiomyocytes from five EDMD patients, gene-corrected isogenic controls, three-dimensional engineered heart tissues, and a Lmna L204P knock-in mouse model. Multi-omics analysis was employed to map chromatin accessibility and transcriptional changes. Pharmacological rescue experiments tested WNT5a supplementation, RhoA activators, and actin polymerization stabilizers.
Study Limitations
This summary is based on the abstract only, as the full text is not open access, so methodological details and data cannot be fully evaluated. The patient cohort is small (five individuals), which is typical for rare diseases but limits generalizability. Mouse models and iPSC systems do not fully replicate human cardiac physiology, and pharmacological rescue experiments have not yet been tested in human patients.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.